Factor V11 or factor V11A GLA domain variants

Details Factor V11 or factor V11A GLA domain variants Factor V11 or factor V11A GLA domain variants

2006-06-14

2010-10-05

Robinson, Hope A (Department: 1652)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S350000

Reexamination Certificate

active

07807638

ABSTRACT:
Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5041376 (1991-08-01), Gething et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5225537 (1993-07-01), Foster
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5460950 (1995-10-01), Barr et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5648254 (1997-07-01), Mulvihill et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824634 (1998-10-01), Merchant
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 5965425 (1999-10-01), Barr et al.
patent: 5986079 (1999-11-01), Barr et al.
patent: 6013620 (2000-01-01), Turecek et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6100061 (2000-08-01), Reiter et al.
patent: 6423826 (2002-07-01), Nelsestuen
patent: 6475725 (2002-11-01), Reiter et al.
patent: 6693075 (2004-02-01), Nelsestuen
patent: 6747003 (2004-06-01), Nelsestuen
patent: 6762286 (2004-07-01), Nelsestuen
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6903069 (2005-06-01), Pingel et al.
patent: 7026524 (2006-04-01), Persson et al.
patent: 7220837 (2007-05-01), Nelsestuen
patent: 2003/0100506 (2003-05-01), Nelsestuen
patent: 2003/0100740 (2003-05-01), Persson et al.
patent: 2003/0104978 (2003-06-01), Persson et al.
patent: 2003/0211094 (2003-11-01), Nelsestuen
patent: 2003/0211460 (2003-11-01), Nelsestuen
patent: 2005/0164932 (2005-07-01), Haaning
patent: 2006/0019336 (2006-01-01), Pedersen et al.
patent: 2006/0111282 (2006-05-01), Haaning
patent: 2006/0116324 (2006-06-01), Persson et al.
patent: 2006/0166874 (2006-07-01), Haaning
patent: 2006/0228782 (2006-10-01), Pedersen
patent: 2006/0240524 (2006-10-01), Pedersen
patent: 2006/0240525 (2006-10-01), Pedersen
patent: 2006/0240526 (2006-10-01), Haaning
patent: 2006/0241041 (2006-10-01), Haaning
patent: 2006/0252127 (2006-11-01), Pedersen
patent: 2006/0252128 (2006-11-01), Haaning
patent: 2006/0252689 (2006-11-01), Pedersen
patent: 2006/0252690 (2006-11-01), Pedersen
patent: 2006/0258585 (2006-11-01), Pedersen
patent: 2006/0270000 (2006-11-01), Haaning
patent: 2006/0270001 (2006-11-01), Haaning
patent: 2006/0270002 (2006-11-01), Haaning
patent: 2006/0276377 (2006-12-01), Haaning
patent: 2007/0054366 (2007-03-01), Andersen
patent: 2007/0117756 (2007-05-01), Haaning
patent: 2007/0142280 (2007-06-01), Pedersen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 512 011 (1992-11-01), None
patent: WO 88/10295 (1988-12-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 92/15686 (1992-09-01), None
patent: WO 94/27631 (1994-12-01), None
patent: WO 96/00577 (1996-01-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 99/03498 (1999-01-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 99/66031 (1999-12-01), None
patent: WO 00/26230 (2000-05-01), None
patent: WO 00/26354 (2000-05-01), None
patent: WO 00/28065 (2000-05-01), None
patent: WO 00/54787 (2000-09-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/83725 (2001-11-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
patent: WO 02/22776 (2002-03-01), None
patent: WO 02/29025 (2002-04-01), None
patent: WO 02/38162 (2002-05-01), None
patent: WO 02/077218 (2002-10-01), None
patent: WO 03/027147 (2003-04-01), None
patent: WO 03/037932 (2003-05-01), None
patent: WO 03/055512 (2003-05-01), None
patent: WO 03/093465 (2003-11-01), None
patent: WO 2004/029091 (2004-04-01), None
patent: WO 2004/083361 (2004-09-01), None
Ruiz et al. Accession No. P98139, Feb. 1, 1996 (enclosed in office action).
Ruiz et al. Accession No. P98139, Feb. 1, 1996, Alignment (enclosed in office action).
U.S. Appl. No. 11/279,514, Pedersen et al., Unpublished.
J. Toomey et al., Localization of the Human Tissue Factor Recognition Determinant of Human Factor VIIa,J. Biol. Chem. 266(29):19198-19202 (1991).
Harvey, Stephen B., et al., “Mutagenesis of the y-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site,” The Journal of Biological Chemistry 278(10):8363-8369 (Mar. 2003).
Henderson, Nicole et al., “Response of factor VII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in vitro whole blood clotting assay: possible correlation to clinical outcome,” Thromb Haemost 88:98-103 (2002).
Stone, Matthew et al., “Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit: the case of factor VIIai and tissue factor,” Biochemistry 41:15820-15825 (2002).
Zhang, Li et al., “The contributions of individual y-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein c to acidic phospholipid vesicles,” The Journal of Biological Chemistry 268 (16):12040-12045 (Jun. 1993).
U.S. Appl. No. 10/031,005, Nelsestuen, Parent application published as.
Arnlijots et al., “Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa,” J. Vasc. Surg., 1997, 25(2):341-346.
Bauer, “Treatment of factor VII deficiency with recombinant factor VIIa,” Haemostasis, 1996, 26 (Suppl. 1):155-158.
Broze et al., “Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII,” J. Clin. Invest., 1985, 76:937-946.
Choudhri et al., “Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage,” J. Exp. Med., 1999, 190:91-99.
Christiansen et al., “Hydrophobic Amino Acid Residues of Human Anticoagulation Protein C that Contribute to its Functional Binding to Phospholipid Vesicles,” Biochemistry, 1995, 34:10376-10382.
Dackiw et al., “Prevention of endotoxin-induced mortality by antitissue factor immunization,” Arch. Surg., 1996, 131:1273-1278.
Dahlback, “Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboemolism,” Blood, 1995, 85:607-614.
Database EMBL, “Coagulation factor VII (EC 3.4.21.21)(Serum prothrombin conversion accelerator),” “Bovine Factor VII. Its purification and complete amino acid sequence,” ID FA7—BOVIN, Aug. 1, 1991 (3 pages).
“Docking of Tissue Factor and Factor VIIa Initiates Blood Coagulation,” at http://www.sdsc.edu.IOTW/week46.96/ (1996).
Esmon et al., “Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C,” J. Biol. Chem., 1982, 257:859-864.
Evans, Jr. and Nelsestuen, “Importance of cis-Proline 22 in the Membrane-Binding Conformation of Bovine Prothrombin,” Biochemistry, 1996, 35:8210-8215.
Evans and Nelsestuen, “Importance of Cis-Proline 22 and the Aromatic Stack (Residues 41-45) for Prothrombin-Membrane Binding,” Protein Sci., 1996, 5(Suppl. 1):163, Abstract #606-S.
Felgner et al., “Lipofection: a highly efficient, lipid-medi

Affiliated with

Also associated with

Rating

Factor V11 or factor V11A GLA domain variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Factor V11 or factor V11A GLA domain variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor V11 or factor V11A GLA domain variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4193804